New diabetes treatments with CV benefit: A changing role for the cardiologist

Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.

Educational information

This educational video is recorded as an independent educational service by PACE-CME to provide different perspectives and opinions from international experts in the field of cardiovascular disease and diabetes. This video may provide support with the interpretation and translation of new findings towards implications for clinical practice.

The educational content reflects the personal opinion of the expert.

Disclosures

Robert J Chilton, MD - Cardiologist, Professor of Medicine, Department of Medicine, Division of Cardiology, The University of Texas Health Science Center, San Antonio, TX, USA